233 related articles for article (PubMed ID: 34625033)
1. Results of the observational prospective RealFLOT study.
Giommoni E; Lavacchi D; Tirino G; Fornaro L; Iachetta F; Pozzo C; Satolli MA; Spallanzani A; Puzzoni M; Stragliotto S; Sisani M; Formica V; Giovanardi F; Strippoli A; Prisciandaro M; Di Donato S; Pompella L; Pecora I; Romagnani A; Fancelli S; Brugia M; Pillozzi S; De Vita F; Antonuzzo L
BMC Cancer; 2021 Oct; 21(1):1086. PubMed ID: 34625033
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
[TBL] [Abstract][Full Text] [Related]
4. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
6. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
7. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
Götze TO; Piso P; Lorenzen S; Bankstahl US; Pauligk C; Elshafei M; Amato G; Reim D; Bechstein WO; Königsrainer A; Mönig SP; Rau B; Schwarzbach M; Al-Batran SE
BMC Cancer; 2021 Oct; 21(1):1158. PubMed ID: 34715810
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
Hofheinz RD; Hegewisch-Becker S; Kunzmann V; Thuss-Patience P; Fuchs M; Homann N; Graeven U; Schulte N; Merx K; Pohl M; Held S; Keller R; Tannapfel A; Al-Batran SE
Int J Cancer; 2021 Sep; 149(6):1322-1331. PubMed ID: 34019698
[TBL] [Abstract][Full Text] [Related]
10. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
11. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
[TBL] [Abstract][Full Text] [Related]
12. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
13. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
[TBL] [Abstract][Full Text] [Related]
14. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
15. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
Lorenzen S; Götze TO; Thuss-Patience P; Biebl M; Homann N; Schenk M; Lindig U; Heuer V; Kretzschmar A; Goekkurt E; Haag GM; Riera-Knorrenschild J; Bolling C; Hofheinz RD; Zhan T; Angermeier S; Ettrich TJ; Siebenhuener AR; Elshafei M; Bechstein WO; Gaiser T; Loose M; Sookthai D; Kopp C; Pauligk C; Al-Batran SE;
J Clin Oncol; 2024 Feb; 42(4):410-420. PubMed ID: 37963317
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).
Erol C; Sakin A; Başoğlu T; Özden E; Çabuk D; Doğan M; Öksüzoğlu B; Yıldırım HÇ; Öner İ; Eryılmaz MK; Dülgar Ö; Aydın D; Doğan N; Özen M; Hacıbekiroğlu İ; Özdemir N; Gürler F; Paksoy N; Karabulut S; Aksoy A; Hızal M; Kahraman S; Şen E; Paydaş S; Çılbır E; Fırat F; Akdeniz N; Özçelik M; Oyman A; Baytemür NK; Acar R; Almuradova E; Karabulut B; Şakalar T; Arak H; Değerli E; Türker S; Alan Ö; Er Ö; Taşçı EŞ; Demir N; Çavdar E; Turhal S; Dede DŞ; Akıncı MB; Yalçın B; Yumuk F; Yalçın Ş; Şendur MAN
Turk J Med Sci; 2022 Aug; 52(4):1022-1032. PubMed ID: 36326360
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
[TBL] [Abstract][Full Text] [Related]
18. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
Nappo F; Fornaro L; Pompella L; Catanese S; Lavacchi D; Spallanzani A; Cappetta A; Puzzoni M; Murgioni S; Barsotti G; Tirino G; Pellino A; Vivaldi C; Strippoli A; Aprile G; Di Donato S; Mazza E; Prisciandaro M; Antonuzzo L; Zagonel V; Cascinu S; De Vita F; Lonardi S
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6601-6611. PubMed ID: 36795195
[TBL] [Abstract][Full Text] [Related]
19. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E
Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868
[TBL] [Abstract][Full Text] [Related]
20. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
